• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230).
  

PubMed=2344964; DOI=10.1016/0090-8258(90)90332-F
Grenman S.E., Worsham M.J., Van Dyke D.L., England B., McClatchey K.D., Babu V.R., Roberts J.A., Maenpaa J.U., Carey T.E.
Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line.
Gynecol. Oncol. 37:188-199(1990)

PubMed=1541432; DOI=10.1016/0090-8258(92)90045-K
Rantanen V., Grenman S.E., Kulmala J., Salmi T., Grenman R.
Radiation sensitivity of endometrial carcinoma in vitro.
Gynecol. Oncol. 44:217-222(1992)

PubMed=7798295; DOI=10.1007/BF01194268
Rantanen V., Grenman S.E., Kulmala J., Alanen K., Lakkala T., Grenman R.
Sublethal damage repair after fractionated irradiation in endometrial cancer cell lines tested with the 96-well plate clonogenic assay.
J. Cancer Res. Clin. Oncol. 120:712-716(1994)

PubMed=8123477; DOI=10.1038/bjc.1994.87; PMCID=PMC1968845
Rantanen V., Grenman S.E., Kulmala J., Grenman R.
Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.
Br. J. Cancer 69:482-486(1994)

PubMed=9887230; DOI=10.1006/gyno.1998.5194
Rantanen V., Grenman S.E., Kurvinen K., Hietanen S.H., Raitanen M., Syrjanen S.M.
p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.
Gynecol. Oncol. 71:352-358(1998)